MAPK
Les MAPK sont une famille de kinases protéiques impliquées dans une variété de processus cellulaires, y compris la croissance, la prolifération, la différenciation et les réponses au stress. La voie de signalisation MAPK comprend plusieurs niveaux, y compris ERK, JNK et p38 MAPK, chacun jouant des rôles distincts dans la fonction cellulaire. La dérégulation de la signalisation MAPK est liée au cancer, aux maladies inflammatoires et aux troubles métaboliques. Chez CymitQuimica, nous offrons un large éventail d'inhibiteurs et d'activateurs de MAPK pour soutenir vos recherches en biologie cellulaire, transduction de signaux et mécanismes des maladies.
886 produits trouvés pour "MAPK"
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
SKF-86002 dihydrochloride
CAS :<p>p38 MAP kinase inhibitor</p>Formule :C16H14Cl2FN3SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :370.27K-Ras G12C-IN-1
CAS :<p>K-Ras G12C-IN-1 is a novel and irreversible inhibitor of mutant K-ras G12C.</p>Formule :C22H23Cl2N3O3Couleur et forme :SolidMasse moléculaire :448.34KRAS G12C inhibitor 25
CAS :<p>KRAS G12C inhibitor 25 blocks SOS1-mediated GDP/GTP swap in KRAS-G12C mutants; IC50: 0.48 nM (WO2021216770A1, comp. 3).</p>Formule :C32H41N7O2Couleur et forme :SolidMasse moléculaire :555.71SOS1-IN-16
CAS :<p>SOS1-IN-16 (Comp 54) serves as a selective SOS1 inhibitor exhibiting an IC50 value of 7.2 nM and demonstrates inhibitory activity against CYP3A4 with an IC50 of</p>Formule :C30H31F3N4O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :552.59HPK1-IN-33
CAS :<p>HPK1-IN-33 inhibits HPK1 with 1.7 nM potency, reduces IL-2 in Jurkat cells with 286 nM EC50, and is less effective in HPK1 KO cells.</p>Formule :C18H16ClFN6Couleur et forme :SolidMasse moléculaire :370.81KRAS G12C inhibitor 53
CAS :<p>KRAS G12C inhibitor 53 (Compound 1) is a KRAS G12C inhibitor.</p>Formule :C21H14ClF2N5O2Couleur et forme :SolidMasse moléculaire :441.82HPK1-IN-11
CAS :<p>HPK1-IN-11 is a potent HPK1 inhibitor. HPK1-IN-11 has potential for the study of HPK1-related diseases.</p>Formule :C27H25N5O2Couleur et forme :SolidMasse moléculaire :451.52pan-KRAS-IN-3
CAS :<p>Pan-KRAS-IN-3 (Example 84) is a pan-KRAS inhibitor suitable for cancer research [1].</p>Formule :C33H32F3N5O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :587.63SB 203580 sulfone
CAS :<p>SB 203580 sulfone, an analog of the p38 MAP kinase inhibitor SB 203580, inhibits IL-1 production in monocytes and binds competitively with CSAID binding proteins (CSBP), inhibiting stress response signaling. It exhibits an IC50 of 0.2 μM for IL-1 inhibition and 0.03 μM for CSBP-mediated signaling inhibition [1].</p>Formule :C21H16FN3O2SCouleur et forme :SolidMasse moléculaire :393.43AZ-TAK1
CAS :<p>"AZ-Tak1 inhibits TAK1 kinase (IC50=0.009mM), reduces p38/ERK levels, and induces apoptosis in Mino, SP53, Jeko cells with increasing efficacy at 0.1-0.5mM."</p>Formule :C25H28FN7O2Couleur et forme :SolidMasse moléculaire :477.53AMG-548 dihydrochloride (864249-60-5 free base)
<p>AMG-548 dihydrochloride: oral p38α inhibitor, Ki: 0.5 nM; less so for p38β, Ki: 36 nM; >> p38γ/δ; blocks LPS-induced TNFα, IC50: 3 nM.</p>Formule :C29H29Cl2N5ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :534.48HPK1-IN-35
CAS :<p>HPK1-IN-35 is a potent, selective inhibitor of HPK1, demonstrating an IC50 value of 3.5 nM.</p>Formule :C30H32N8O3SCouleur et forme :SolidMasse moléculaire :584.69Rac1-IN-3
CAS :<p>Rac1-IN-3 (Compound 2) is a Rac1 inhibitor exhibiting an inhibitory concentration 50 (IC50) of 46.1 μM [1].</p>Formule :C21H23N7O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :405.45BI-0474
CAS :<p>BI-0474: KRASG12C inhibitor, IC50=7.0 nM, blocks GDP-KRAS/SOS1, anti-tumor in NCI-H358 cells & lung cancer model, for cancer research.</p>Formule :C30H37N9O2SDegré de pureté :99.61%Couleur et forme :SolidMasse moléculaire :587.74FGTI-2734 mesylate (1247018-19-4 free base)
CAS :<p>FGTI-2734 mesylate hinders KRAS, overcoming resistance and targeting pancreatic tumors; inhibits FT and GGT with IC50s of 250 nM, 520 nM.</p>Formule :C27H35FN6O5S2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :606.73(R)-VX-11e
CAS :<p>(R)-VX-11e is an isomer of VX-11e, a potent and selective ERK2 inhibitor with potential to inhibit tumor growth.</p>Formule :C24H20Cl2FN5O2Degré de pureté :98.73%Couleur et forme :SolidMasse moléculaire :500.35ERK-IN-2 free base
CAS :<p>ERK-IN-2 free base inhibits ERK2 (IC50: 1.8 nM); potential off-target effects at >10 μM.</p>Formule :C16H17N5O2Couleur et forme :SolidMasse moléculaire :311.34KRAS G12C inhibitor 59
CAS :<p>KRAS G12C Inhibitor 59 is a compound with anticancer properties.</p>Formule :C32H39F6N7O5Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :715.69KRAS inhibitor FB9
CAS :<p>KRAS inhibitor FB9 can be used in studies about Ras.</p>Formule :C23H21ClF4N2O5Couleur et forme :SolidMasse moléculaire :516.87HPK1-IN-12
CAS :<p>HPK1-IN-12 is a potent inhibitor of HPK1. HPK1-IN-12 has potential for the study of HPK1-related diseases.</p>Formule :C25H24FN5O2Couleur et forme :SolidMasse moléculaire :445.49KRAS G12C inhibitor 32
CAS :<p>KRAS G12C Inhibitor 32, an eight-membered heterocyclic compound with nitrogen, acts as a potent inhibitor of KRAS G12C [1].</p>Formule :C29H30Cl3FN6O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :635.94DL-threo dihydrosphingosine
CAS :<p>DL-threo dihydrosphingosine blocks ERK, inhibits smooth muscle proliferation, and works against growth factor/G-protein ERK activation.</p>Formule :C18H39NO2Couleur et forme :SolidMasse moléculaire :301.51MNK inhibitor 9
CAS :<p>MNK inhibitor 9 potently blocks MNK1/2 (IC50: 0.003 µM each), is cell-permeable, and useful for tumor research.</p>Formule :C25H29N9OCouleur et forme :SolidMasse moléculaire :471.56ERK1/2 inhibitor 7
CAS :<p>ERK1/2 inhibitor 7 is a potent inhibitor of ERK, acting on ERK2 (IC50: 0.94 nM).</p>Formule :C23H22FN7OSCouleur et forme :SolidMasse moléculaire :463.53KRAS inhibitor-11
<p>KRAS inhibitor-11 is a KRAS inhibitor .</p>Formule :C29H47N9O6Couleur et forme :SolidMasse moléculaire :617.74Inflachromene
CAS :<p>Inflachromene (ICM) is an inhibitor of HMGB1 and HMGB expression with anti-inflammatory activity.Inflachromene is used in the study of epilepsy.</p>Formule :C21H19N3O4Degré de pureté :97.36% - 99.88%Couleur et forme :SolidMasse moléculaire :377.39SOS1-IN-13
CAS :<p>SOS1-IN-13 inhibits SOS1 (IC50: 6.5 nM) and pERK (327 nM); potential in cancer research.</p>Formule :C21H22F3N3O2Couleur et forme :SolidMasse moléculaire :405.41KRAS G12C inhibitor 1R
CAS :<p>KRAS G12C inhibitor 1R can be used in studies about Ras.</p>Formule :C31H36ClFN6O2Couleur et forme :SoildMasse moléculaire :579.11Raf inhibitor 3
CAS :<p>Raf inhibitor 3 (Example 30), a potent inhibitor of both B-Raf and C-Raf, exhibits IC50 values below 15 nM. It is applicable in cancer research studies [1].</p>Formule :C18H19FN8O2SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :430.46Laxiflorin B
CAS :<p>Laxiflorin B, a novel selective inhibitor of ERK 1/2 derived from herbal sources, exhibits antitumor activity [1].</p>Formule :C20H24O5Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :344.4HPK1-IN-13
CAS :<p>HPK1-IN-13 is a potent inhibitor of HPK1. HPK1-IN-12 has potential for the study of HPK1-related diseases.</p>Formule :C25H24FN5O2Couleur et forme :SolidMasse moléculaire :445.49GSK1790627
CAS :<p>GSK1790627, the N-deacetylated metabolite of Trametinib, represents an orally active MEK inhibitor that promotes autophagy and triggers apoptosis [1].</p>Formule :C24H21FIN5O3Couleur et forme :SolidMasse moléculaire :573.36Glecirasib
CAS :<p>Glecirasib (JAB-21822,KRAS G12C inhibitor 36) is an orally active KRAS G12C inhibitor that selectively binds to and inhibits KRAS G12C-dependent signaling</p>Formule :C31H26ClF4N7O2Degré de pureté :99.7% - >99.99%Couleur et forme :SolidMasse moléculaire :640.03ZG1077
CAS :<p>ZG1077, a covalent KRAS G12C inhibitor, is utilized in non-small cell lung cancer (NSCLC) research.</p>Formule :C33H33F2N5O5SCouleur et forme :SolidMasse moléculaire :649.71HPK1-IN-27
CAS :<p>HPK1-IN-27 inhibits HPK1 (MAP4K1), a kinase with potential for cancer treatment, per patent WO2019016071A1, compound 38.</p>Formule :C26H23F3N4O4Couleur et forme :SolidMasse moléculaire :512.48Org OD 02-0
CAS :<p>10-Ethenyl-19-norprogesterone (Org OD 02-0) is a selective agonist for the membrane progesterone receptor α (mPRα) with an IC50 of 33.9 nM, known to activate</p>Formule :C22H30O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :326.47B-Raf IN 15
CAS :<p>B-Raf IN 15 is a BRAF inhibitor that inhibits BRAFWT and BRAFV600E and can be used to study melanoma and cancer.</p>Formule :C19H15N3OSDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :333.41KRAS G12C inhibitor 61
CAS :<p>KRAS G12C inhibitor 61 (Example 3) demonstrates potent activity by inhibiting phospho-ERK 1/2 in MIA PaCa-2 cells, reflected in an IC50 value of 9 nM.</p>Formule :C31H33ClFN7O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :590.09ERK1/2 inhibitor 9
CAS :<p>ERK1/2 Inhibitor 9 (Probe 1), a covalent antagonist of ERK1/2, exhibits sub-micromolar efficacy in cellular assays (A375 GI50=0.47 μM) and facilitates the</p>Formule :C31H32ClN7O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :586.08FGTI-2734
CAS :<p>FGTI-2734, a dual FT/GGT-1 inhibitor (IC50: 250/520 nM), blocks KRAS membrane binding and curbs KRAS-driven pancreatic cancer.</p>Formule :C26H31FN6O2SDegré de pureté :99.69%Couleur et forme :SolidMasse moléculaire :510.63GNE 220
CAS :<p>GNE-220 is a potent and selective inhibitor of MAP4K4 (IC50: 7 nM).</p>Formule :C25H26N8Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :438.53XRP44X
CAS :<p>XRP44X (XRP 44X) is a potent inhibitor of Ras-Net (Elk-3) pathway.</p>Formule :C21H21ClN4ODegré de pureté :99.67%Couleur et forme :SolidMasse moléculaire :380.87DT-061
CAS :<p>DT-061 is an orally bioavailable protein phosphatase 2A (PP2A) activator. It could be applied in the therapy of KRAS-mutant and MYC-driven tumorigenesis.</p>Formule :C25H23F3N2O5SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :520.52KRAS G12C inhibitor 16
CAS :<p>KRAS G12C inhibitor 16 is a potent KRAS G12C inhibitor.</p>Formule :C24H21ClFN3O3Degré de pureté :97.84%Couleur et forme :SolidMasse moléculaire :453.89CXJ-2
CAS :<p>CXJ-2, a cyclic peptide, binds EDPs, inhibits PI3K/ERK, and reduces hepatic cell growth/migration, offering antifibrotic effects.</p>Formule :C55H87N15O22Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :1310.37KRAS G12C inhibitor 58
CAS :<p>KRAS G12C inhibitor 58 is utilized in cancer research as an inhibitor of the KRAS G12C mutation [1].</p>Formule :C51H64ClF4N9O8SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :1074.62KRAS degrader-1
CAS :<p>KRAS degrader-1 (compound 1) is a potent agent that selectively targets KRAS proteins for destruction via the autophagy-lysosomal degradation pathway [1].</p>Formule :C55H57Br2ClFIN8O7Couleur et forme :SolidMasse moléculaire :1283.25KRAS G12D modulator-1
CAS :<p>KRAS G12D modulator-1 (compound 6), a potent modulator of KRAS G12D, exhibits IC50 values ranging from 1-10 μM against NEA-G12D, PPI-G12D, and p ERK-AGS, and is</p>Formule :C30H36FN5O4Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :549.64Ilaprazole sodium hydrate
CAS :<p>Ilaprazole sodium hydrate (IY-81149 sodium hydrate) is a proton pump inhibitor that blocks the transport of HSV particles.</p>Formule :C19H21N4NaO4SDegré de pureté :99.2%Couleur et forme :SolidMasse moléculaire :424.45pan-KRAS-IN-2
CAS :<p>Pan-KRAS-IN-2 (compound 6) is a broad-spectrum KRAS inhibitor exhibiting potent activity with IC50 values of ≤10 nM against KRAS wild type and its mutants (G12D</p>Formule :C34H34F2N4O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :584.66
